Related Experiment Video
Updated: Dec 21, 2025

04:30
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
Published on: March 8, 2024
1.4K
COVID 19: Neuromuscular Manifestations
Rajesh Benny1, Satish V Khadilkar2
1Senior Consultant and Associate Professor of Neurology, Fortis Hospital, Mumbai, Maharashtra, India.
Annals of Indian Academy of Neurology
|May 19, 2020
Summary
The COVID-19 pandemic presents with uncommon neuromuscular manifestations. This review analyzes current information on these neurological effects of the virus.
Area of Science:
- Neurology
- Infectious Diseases
- Virology
Background:
- The ongoing COVID-19 pandemic necessitates understanding its diverse clinical presentations.
- Neurological complications of viral infections are increasingly recognized.
- Early reports suggest neuromuscular involvement in some COVID-19 cases.
Purpose of the Study:
- To systematically review and synthesize available data on neuromuscular manifestations associated with COVID-19.
- To consolidate current knowledge regarding the spectrum of neurological symptoms in COVID-19 patients.
Main Methods:
- Literature search of scientific databases for studies reporting neuromuscular symptoms in COVID-19 patients.
- Analysis of reported cases focusing on neurological and muscular symptoms.
- Synthesis of findings to describe the characteristics of neuromuscular involvement.
Main Results:
- Neuromuscular manifestations are reported, though uncommonly, in the context of COVID-19.
- Observed symptoms include peripheral neuropathy, myopathy, and neuromuscular junction disorders.
- The precise mechanisms underlying these manifestations are still under investigation.
Conclusions:
- COVID-19 can present with a range of neuromuscular complications.
- Further research is crucial to elucidate the pathophysiology and clinical impact of these neurological findings.
- Awareness among clinicians is important for timely diagnosis and management of COVID-19-related neuromuscular issues.
Keywords:
COVID-19 neurological manifestationsCOVID-19 neuromuscular manifestationsguillain barre syndromemyositisMore Related Videos
Related Concept Videos
Disorders of the Skeletal Muscle
1.6K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.6K
Myasthenia Gravis: Diagnostic Tests
1.8K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.8K
Skeletal Muscle Relaxants: Adverse Effects
713
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
713
Chemical Synapses
11.0K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
11.0K
Chemical Synapses
4.0K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
4.0K
Myasthenia Gravis: Overview and Treatment
2.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.6K

